The global incidence of metabolic syndrome （MetS） is dramatically increasing. Considerable interest has been devoted to the relationship between MetS and prostate cancer （PCa） risk. However, few studies have exami...The global incidence of metabolic syndrome （MetS） is dramatically increasing. Considerable interest has been devoted to the relationship between MetS and prostate cancer （PCa） risk. However, few studies have examined the association between MetS and PCa progression. This retrospective study consisted of 1016 patients with PCa who received radical prostatectomy. The association between MetS and pathological features was evaluated using logistic regression analysis. Compared with patients without MetS, those with MetS indicated an increased risk of prostatectomy Gleason score （GS）≥8 （odds ratio [OR] =1.670, 95% confidence interval （CI） 1.096-2.545, P = 0.017）, and a 1.5-fold increased risk of pT3-4 disease （OR = 1.583, 95% CI 1.106-2.266, P = 0.012）. The presence of MetS was an independent predictor of lymph node involvement （OR = 1.751, 95% CI 1.038-2.955, P = 0.036）. Furthermore, as the number of MetS components accumulated, the risk of a GS ≥ 8 increased. The present study indicates a significant association between MetS and advanced PCa. The results need to be evaluated in large-scale prospective cohorts.展开更多
基金This study was supported in part by grant from the National Natural Science Foundation of China （No. 81272837）.
文摘The global incidence of metabolic syndrome （MetS） is dramatically increasing. Considerable interest has been devoted to the relationship between MetS and prostate cancer （PCa） risk. However, few studies have examined the association between MetS and PCa progression. This retrospective study consisted of 1016 patients with PCa who received radical prostatectomy. The association between MetS and pathological features was evaluated using logistic regression analysis. Compared with patients without MetS, those with MetS indicated an increased risk of prostatectomy Gleason score （GS）≥8 （odds ratio [OR] =1.670, 95% confidence interval （CI） 1.096-2.545, P = 0.017）, and a 1.5-fold increased risk of pT3-4 disease （OR = 1.583, 95% CI 1.106-2.266, P = 0.012）. The presence of MetS was an independent predictor of lymph node involvement （OR = 1.751, 95% CI 1.038-2.955, P = 0.036）. Furthermore, as the number of MetS components accumulated, the risk of a GS ≥ 8 increased. The present study indicates a significant association between MetS and advanced PCa. The results need to be evaluated in large-scale prospective cohorts.
